Loading...
ROCO
3294
Market cap130mUSD
Oct 08, Last price  
31.50TWD
1D
-1.41%
1Q
-16.45%
Jan 2017
92.66%
IPO
-20.09%
Name

Megaforce Co Ltd

Chart & performance

D1W1MN
ROCO:3294 chart
P/E
—
P/S
1.17
EPS
—
Div yield, %
1.21%
Shrs. gr., 5y
-0.08%
Rev. gr., 5y
-6.87%
Revenues
3.57b
-17.24%
4,667,355,0007,059,946,0008,058,028,0005,642,662,0006,709,445,0006,414,740,0004,928,472,0005,155,620,0004,858,636,0005,915,570,0005,170,334,0005,384,067,0004,825,632,0005,000,238,0005,093,357,0005,319,553,0004,834,937,0004,138,158,0004,312,502,0003,568,957,000
Net income
-64m
L
343,599,000348,937,00031,774,000-175,244,000-145,523,000300,727,000-183,488,000-81,025,000-193,138,00078,351,000117,436,000216,554,000793,00030,532,00085,706,00023,994,000-156,567,000-129,394,00075,623,000-64,376,999
CFO
82m
-60.20%
0145,058,000239,461,000324,489,000380,287,000204,872,00081,541,000
Dividend
Apr 01, 20250.38 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Megaforce Company Limited, founded in 1991 and headquartered in New Taipei City, Taiwan, is a global enterprise specializing in advanced plastic components and opto-mechatronic services. The company's operations extend across Taiwan, China, Mexico, and the United States. Megaforce boasts a comprehensive suite of capabilities, including precision plastic injection molding, the development of micro-precision structural molds, electronic assembly, spray printing, and liquid silicone rubber molding. Their expertise also covers design for manufacturing (DFM), tooling, surface treatment, post-processing, and assembly services. Furthermore, they are involved in the development of critical materials and the design of intricate mechanical and material processes. Beyond core manufacturing, the company offers a range of specialized products and services, particularly in the medical field. These include dental electromechanical integration products, components for da Vinci surgical systems, IoT-enabled medical integration solutions, and various medical machinery. They also provide medical teaching courses. Megaforce's diverse product portfolio serves a wide array of high-tech industries. Their components are integral to advanced computer gaming and home entertainment equipment, vehicle components, medical appliances, and aerospace equipment, as well as the broader computer, communication, and consumer electronics (3C) sectors.

Key people

Wen-Lin Hsu
Chairman of the Board, Chief Executive Officer · since 2021
Frank Lee
General Manager-Megaforce Shanghai BU · since 2012
Tung-Hui Chiang
Vice Chairman of the Board, General Manager, Chief Information Security Officer · since 2023
Stanley Hsu
Deputy General Manager-Megaforce Dongguan BU · since 2021
Hawk Lin
Deputy General Manager-Megaforce Taiwan BU · since 2016
Chief Strategy Officer · since 2019
Yanhua Huang
Corporate Governance Officer · since 2024
Makoto Masuda
Chief Research & Development Officer-Optp-electronic BU · since 2019
Rick Chang
Chief Financial Officer, Head of Finance & Accounting, Director · since 2024
Minxiong Chu
Director · since 2024
Wan-Sheng Hsu
Director · since 2015
Lee Lu
Director · since 2024
Haibang Jiang
Independent Director · since 2006
Weijun Jin
Independent Director · since 2024
Wanhua Xie
Independent Director · since 2024
IPO date
Oct 14, 2005
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT